Unintentional fatal overdose of veterinary levamisole in a human subject.

J Forensic SciJun 19, 2026 (epub)
Case ReportEmergency MedicineInternal Medicine (General)Open access

Rebecca Kusko, Serah Oyewole, Robert D Johnson et al.

✦ AI-curated · Sources linked

Case in brief

A patient presented with nausea, vomiting, tremors, and visual changes after an oral ingestion of levamisole, leading to bradycardia and pulseless electrical activity cardiac arrest. Despite treatment efforts, the patient succumbed. Post-mortem testing confirmed levamisole at a concentration of 19,000 ng/mL, establishing the cause of death as levamisole overdose.

Diagnostic / clinical pearl

Clinicians should be aware that levamisole can cause severe toxicity, including cardiovascular collapse, even in the absence of coingestants.

Source

PubMed · PMID 42321982Free full text on PubMed Central

Published in J Forensic Sci. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Emergency Medicine

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.